AtriCure Inc. (ATRC) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ATRC scores 63 out of 100, graded C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine: 10 / 20. Per the RQD rating, this pillar reflects ROIC of -1.9% and an FCF yield of 1.52%. Returns on invested capital are negative, so this is the weakest pillar relative to its weight. For a prospective investor, the upside case here depends on the business converting its reported cash generation into sustained positive returns, which the source data does not yet show.
• Whale 13F Flow: 17 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. It is the strongest pillar. The source data describes this only as a score; the underlying 13F holder detail is not available in source data.
• Insider Conviction: 8 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is a below-midpoint reading, and the underlying insider transaction detail is not available in source data.
• Macro Regime Fit: 12 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is factored. A beta of 1.0 implies market-matching sensitivity rather than amplified volatility, but the score indicates only moderate alignment with the current regime.
• Forensic Balance Sheet: 16 / 20. Per the RQD rating, Altman Z is 12.08, Piotroski F is 8/9, and Debt/Equity is 0.13. This is the second-strongest pillar and signals a low-leverage, financially sound balance sheet even while operating results are negative.

Taken together, the investor implication is a trade-off. The balance sheet and institutional positioning provide support, while weak cash returns and insider signals temper the case. The valuation tradeoff is that the stock trades at a market capitalization of $3.18B against negative operating and net margins, so the price relies on expectations of future improvement that the reported figures do not yet confirm. The 52-week range of $25.36 to $63 shows the stock has moved substantially, with the current price of 62.48 near the top of that range.

AtriCure Inc. (ATRC) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. Per the company profile, it has a market capitalization of $3.2B. The source data does not describe its specific products, customer base, or revenue model. Per the SEC financials, the company reported revenue of $534.5M for FY 2025, indicating an operating business of meaningful scale.

Per the SEC financials, revenue grew from $399.2M in FY 2023 to $534.5M in FY 2025, and operating losses narrowed from $-40.0M in FY 2024 to $-9.4M in FY 2025. Per the market data, gross margin is 75%, operating margin is -1.8%, net margin is -2.1%, and ROIC is -1.9%. Per the Roarable RQD rating, the Altman Z-Score is 12.08 and the Piotroski F-Score is 8/9, both supportive readings. Per the SEC financials, FY 2025 cash of $167.4M exceeds debt of $61.9M, and the RQD rating reports Debt/Equity of 0.13.

Per the recent news feed, six headlines were captured. Two items are tagged CATALYST and carry a GREEN light, one describing a fair value adjustment tied to procedure growth and risks, and one describing a share price move of 3.9%. Two items are tagged CATALYST as well, including a technical report on the stock testing resistance. Two MARKET WIRE items carry YELLOW lights, including a Simply Wall St report characterizing the stock as overvalued on its sales. Risk watch items are the overvaluation framing in the Simply Wall St coverage and the mixed sentiment across the feed. Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals, so this section has no butterfly-sourced catalysts.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies are therefore not available in source data. Sector classification is Health Care, Medical/Dental Instruments. Sector correlations and 2nd-order bottlenecks are not available in source data.

Analyst data is not available in source data. Holder data, including SEC Form 4 insider, 13F, and Congressional trades, is not available in source data. The RQD rating's whale and insider pillar scores are the only indirect references to ownership activity in the source data.

• What are the company's specific products and revenue model, given the source data provides only sector and industry classification?
• What is the source of the net losses and negative ROIC, and what is management's trajectory toward positive operating margins?
• Why do EPS, P/E, and EV/EBITDA remain unavailable, and how would these valuation metrics compare to peers?
• What is the detail behind the 13F institutional accumulation and insider Form 4 cluster flows reflected in the RQD pillar scores?
• What drove the FY 2025 swing in FCF from $0.7M to $48.3M, and is that cash generation repeatable?